Lung cancer trials in Germany

In Germany 182 Also abroad 2733

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Where
Dresden, Giessen, Kassel, Regensburg
Age
18 years and over
People
220 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05967689
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Bayern, Berlin, Heidelberg, Mainz
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Mannheim, Regensburg
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Cologne, Giessen, Hamburg, Heidelberg, Jena, Wuerzburg
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Where
Aachen, Berlin, Bonn, Essen, Gauting, Großhansdorf, Halle, Heidelberg, Homburg, Kassel, München, Stuttgart
Age
18 years and over
People
363 worldwide
Run by
OSE Immunotherapeutics
See details and how to joinNCT06472245
Phase 3Taking people
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
Where
Berlin, Bochum, Goettingen
Age
18 years and over
People
120 worldwide
Run by
Pharmacosmos A/S
See details and how to joinNCT07473128 · EU 2025-525026-35-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Essen, Heidelberg, Herne, Jena, Nuertingen, Tuebingen
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Heidelberg, Tuebingen
Age
18 years and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Berlin, Esslingen am Neckar, Grosshansdorf, Immenhausen, Munich, Velbert
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
No phaseTaking people
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Where
Bad Homburg, Berlin, Bremen, Celle, Chemnitz, Cologne, Deggendorf, Frankfurt, Georgsmarienhütte, Gera, Goslar, Greifswald, Halle-Dolau, Hanover, Herne, Hösbach, Koblenz, Koln-Mehrheim, Mainz, Marburg, Münnerstadt, Neuss, Offenbach, Querfurt, Ravensburg, Rüsselsheim am Main, Treuenbrietzen, Ulm, Wiesbaden, Zwickau
Age
18 years to 120 years
People
600
Run by
AstraZeneca
See details and how to joinNCT06494540
Phase 3Taking people
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Where
Bad Berka, Berlin, Chemnitz, Cologne, Esslingen am Neckar, Gauting, Giessen, Grosshansdorf, Halle (saale), Kassel, Koblenz, Loewenstein, Luebeck, Oldenburg in Holstein, Traunstein, Treuenbrietzen, Ulm
Age
18 years and over
People
714 worldwide
Run by
Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Amberg, Augsburg, Bad Saarow, Berlin, Bonn, Brunswick, Essen, Flensburg, Hamburg, Heidelberg, Immenhausen, Koblenz, Leipzig, Loewenstein, Munich, Offenbach Am Main, Oldenburg, Schweinfurt, Trier, Velbert, Wuerzburg, Wuppertal
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 4Taking people
A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy
Where
Heidelberg
Age
18 years and over
People
550 worldwide
Run by
Intuitive Surgical
See details and how to joinNCT07761351
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Cologne
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Cologne, Dresden, Essen, Freiburg im Breisgau, Gauting, Greifswald, Grosshansdorf, Heidelberg, Kassel, Minden, Regensburg, Stuttgart, Wuerzburg
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 1Taking people
A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Where
Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Immenhausen, Moers
Age
18 years and over
People
180 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509572-42-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Cologne, Esslingen am Neckar, Moers, Nuremberg
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Essen, Munich
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Chemnitz, Cologne, Erlangen, Esslingen, Gauting, Giessen, Goettingen, Halle (saale), Hanover, Herne, Karlsruhe, Minden, Moers, Stuttgart
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Cologne, Frankfurt Am Main, Halle (saale), Munich, Wuerzburg
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
Phase 1Taking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Essen
Age
18 years and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
Where
Berlin, Chemnitz, Cologne, Gauting, Grosshansdorf, Heidelberg, Kiel, Luebeck
Age
18 years and over
People
168 worldwide
Run by
Amgen Inc.
See details and how to join2026-525489-23-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Hamburg, Heilbronn, Munich
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
No phaseTaking people
Lung cAncer Robotic Comparative Study
Where
Heidelberg, Regensburg
Age
18 years and over
People
600 worldwide
Run by
Intuitive Surgical
See details and how to joinNCT06038227